◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

HomeAll stocksARWR › EPS

Arrowhead Pharmaceuticals Inc (ARWR) EPS 2006–TTM

DATA UPDATED 2026-09-19

Arrowhead Pharmaceuticals Inc annual earnings per share (EPS) for fiscal TTM was $-2.25, a decrease of 22,400.0% from $-0.01 in fiscal 2025. All figures are reported results from public filings — no estimates or projections.

ARWR Annual EPS

EPS (annual)TTM → 2026-06-302025-09-302024-09-302023-09-302022-09-302021-09-302020-09-302019-09-302018-09-302017-09-302016-09-302015-09-302014-09-302013-09-302012-09-302011-09-302010-09-302009-09-302008-09-302007-09-302006-09-30
Earnings Per Share (EPS)$-2.25$-0.01$-5.00$-1.92$-1.67$-1.36$-0.84$0.69$-0.65$-0.47$-1.34$-1.60$-1.25$-1.30$-1.90$-0.44$-0.90$-4.27$-6.91$-8.35$-5.95

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ARWR Quarterly EPS

EPS (quarterly)2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-30
Earnings Per Share (EPS)$-1.36$-0.93$0.22$-0.18$-1.26$2.75$-1.39$-1.40$-1.38

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

EPS at Comparable Companies

More ARWR metrics: Revenue · Gross Profit · Operating Income · Net Income · EBITDA · Free Cash Flow · Shares Outstanding

All ARWR financial statements → Interactive ARWR charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.